The company said it plans to move all its immunoassays to a single vendor, representing an opportunity worth between $250 million and $400 million annually.
The Australian Red Cross Blood Service will use the Alinity s System to process its blood tests and improve lab automation.
Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.
The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine.
The test can be used to help doctors in the emergency room diagnose heart attacks faster and more accurately than other troponin tests on the market, Abbott said.
The algorithm uses age, sex, and information about troponin concentrations in patients to determine the likelihood of a heart attack.
According to industry groups, some vendors are reporting providers have returned POC testing systems because the economics of using them no longer makes sense.
A recent study from UCSF suggests Abbott's blood-based i-Stat Alinity device may be able to identify TBI that isn't found by a CT scan.
The firm anticipates that point-of-care adoption may attract licensing deals from companies interested in adding the biomarkers to their large laboratory analyzers.